SCHEMBL4521156

SCHEMBL4521156

COc1ccc(Oc2ccc(S(=O)(=O)N[C@@H](C)COc3cccc4ncccc34)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 8/20 0.63
POLB P06746 2/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
RECQL P46063 1/20 0.42
GLO1 Q04760 1/20 0.42
SLC40A1 Q9NP59 1/20 0.42
ADAMTS4 O75173 1/20 0.42
MMP13 P45452 1/20 0.42
GAA P10253 1/20 0.41
HTR7 P34969 1/20 0.41
RAB9A P51151 1/20 0.41
CKS1B P61024 1/20 0.41
SKP2 Q13309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519425 0.92 NR3C1 (0.63) NR3C1ALDH1A1SMN1; SMN2ADAMTS4MMP13
SCHEMBL4507730 0.84 NR3C1 (0.66) NR3C1POLBALDH1A1
SCHEMBL4517669 0.82 NR3C1 (0.73) NR3C1POLBALDH1A1LMNAHTT
SCHEMBL4517545 0.77 NR3C1 (1.00) NR3C1GLO1SLC40A1
SCHEMBL13889061 0.77 NR3C1 (0.46) NR3C1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL4528605 0.77 NR3C1 (0.66) NR3C1SMN1; SMN2GAA
SCHEMBL4510931 0.77 NR3C1 (0.77) NR3C1
SCHEMBL4501289 0.77 NR3C1 (0.61) NR3C1ALDH1A1HTR7
SCHEMBL4516862 0.76 NR3C1 (1.00) NR3C1
SCHEMBL4515955 0.76 NR3C1 (0.66) NR3C1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885POLB 4298/4885ALDH1A1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.